Short Bowel Syndrome

WASHINGTON — In a Healio video, Kishore R. Iyer, MBBS, shares results from the STARS study, in which weekly apraglutide significantly reduced parenteral support volume in patients with short bowel syndrome and intestinal failure.

Topline results from the phase 3 STARS trial showed apraglutide reduced dependency on parenteral support for adult patients with short bowel syndrome with intestinal failure at week 24, Ironwood Pharmaceuticals announced.

Treatment with apraglutide resulted in a 52% reduction in weekly parenteral support volume at 1 year among nine patients with short bowel syndrome with intestinal failure and colon-in-continuity, according to data presented at UEG week.

After 26 weeks of retreatment with infliximab, 35% of patients with Crohn’s disease achieved remission, according to recent data.

The AGA has released a clinical practice update and expert review on the characterization and management of patients with short bowel syndrome, which recently was published in Clinical Gastroenterology and Hepatology.

A clinical trial for a new treatment for short bowel syndrome is under way, according to the manufacturer, 9 Meters Bioparma.

Gattex, a recombinant human glucagon-like peptide-2, helped pediatric patients with short bowel syndrome-associated intestinal failure reduce their need for parenteral support, according to results of a phase 3 trial.

There is no definitive cure for patients suffering from gastroparesis.

Using probiotics can lead to bacterial growth in the small intestine, causing brain fog and rapid abdominal bloating, according to research published in Clinical and Translational Gastroenterology.